

# **Issues in the Treatment of GIST in South Korea**

Yoon-Koo Kang

Asan Medical Center, University of Ulsan,  
Seoul, Korea

# Strength of Korea in the Treatment of GIST

- Nationwide medical insurance system
- Easy access to expert physicians and hospitals because Korea is a small country
- Strong patient advocacy group



아산 기스트 환우회

<https://cafe.naver.com/koreagist>



# Access to new agents

- **Avapritinib**


- We have participated in global clinical trials of avapritinib (phase I Navigator and phase 3 Voyager trials)
- Now patients with D842V-mutant GISTs can be treated in EAP
- No application to Korean FDA yet

- **Ripretinib**

- We have participated in phase 3 Intrigue trial for 2<sup>nd</sup> line GISTs)
- No EAP or application to Korean FDA yet



# No reimbursement of Imatinib Resumption

- Even though benefit has been demonstrated in RIGHT study
- Because of no difference in OS: due to cross-over allowed



# Mandatory CT scan every 3 months

- Mandatory CT scan at least every 3 months for TKI treatment including 1<sup>st</sup> line imatinib to be reimbursed.
- Concerns about radiation hazard and renal dysfunction (due to contrast dye) with frequent CT scan
- An issue for those with metastatic GIST who are maintained with no visible tumors for many years after imatinib treatment alone or in combination with surgical resection of residual lesions



**Thank you.**